



Harnessing the power of T cell measurement

December 02, 2013

Oxford Immunotec Global PLC Announces Closing of Initial Public Offering and Exercise of Over-Allotment Option

Oxford, UK and Marlborough, MA, December 02, 2013 – Oxford Immunotec Global PLC (NASDAQ: OXFD) today announced the closing of its initial public offering of 6,164,000 ordinary shares at an initial public offering price of \$12.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to 804,000 additional ordinary shares. Oxford estimates net proceeds from the offering to be approximately \$62.8 million after deducting underwriting discounts and commissions and estimated offering expenses. The ordinary shares are listed on The NASDAQ Global Market under the trading symbol "OXFD."

J.P. Morgan Securities LLC and Piper Jaffray & Co. acted as joint book-running managers for the offering. Cowen and Company, LLC and Robert W. Baird & Co. Incorporated acted as co-managers.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on November 21, 2013. The offering was made only by means of the written prospectus, copies of which may be obtained by contacting: J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, or by telephone at (866) 803-9204, or from Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, Minnesota 55402 or by telephone at (800) 747-3924, or by e-mailing a request to prospectus@pjc.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

- Ends -

Notes to Editors:

About Oxford Immunotec Global PLC

Oxford Immunotec Global PLC is a global, commercial-stage diagnostics company committed to improving patient care by providing advanced, innovative tests in the field of immunology. Its proprietary T-SPOT technology platform allows it to measure the responses of specific immune cells, known as T cells, to inform the diagnosis, prognosis and monitoring of patients with immunologically controlled diseases. T cells are a central component of the human body's immune system, and are implicated in the control and progression of many medical conditions, including certain types of infectious diseases, cancers and autoimmune diseases. Oxford Immunotec Global PLC is headquartered near Oxford, UK and in Marlborough, MA.

Website: www.oxfordimmunotec.com

Media Relations

Beth Elkins
Oxford Immunotec Global PLC
+44 1235 442780
belkins@oxfordimmunotec.com

Investor Relations

Richard M. Altieri
Oxford Immunotec Global PLC
Chief Financial Officer
+1 508-481-4648
raltieri@oxfordimmunotec.com